Wealthy Families Play A Growing Role in European Biotech Financing
Executive SummaryThe continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
You may also be interested in...
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
Private German biotech CureVac wins validation for its RNA-vaccine technology platform with Sanofi Pasteur option deal and enters $33 million research collaboration co-funded by U.S defense department.